LogoThe Incretin Space
Login
Subscribe
LogoThe Incretin Space

Amylin

That other beta cell product

GLP-1

+3

ADA Conference 2026: Zenagamtide, Berobenatide, UBT251, enicepatide & orforglipron

Jul 2, 2026

•

14 min read

ADA Conference 2026: Zenagamtide, Berobenatide, UBT251, enicepatide & orforglipron

Orals, Triples, Biologics and even more data from ADA 2026

David W
David W

GLP-1

+4

Eloralintide + Tirzepatide = Bariatric Surgery results!

Jul 1, 2026

•

5 min read

Eloralintide + Tirzepatide = Bariatric Surgery results!

New phase 1b data shows incredible weight loss

David W
David W

GLP-1

+2

ADA Conference 2026: CagriSema & Survodutide

Jun 19, 2026

•

18 min read

ADA Conference 2026: CagriSema & Survodutide

A tale of dual agonists, glucagon or amylin, who wins the insulin sensitivity race?

David W
David W

GLP-1

+6

ADA Conference 2026 Preview

May 29, 2026

•

10 min read

ADA Conference 2026 Preview

The Super Bowl Conference for diabetes and incretins!

GLP-1

+2

More amylin updates & more tolerable drugs(finally)?

Mar 11, 2026

•

11 min read

More amylin updates & more tolerable drugs(finally)?

More early trial results from some new players in the obesity medicine space

Amylin

The conundrum of amylin/calcitonin agonists

Feb 18, 2026

•

19 min read

The conundrum of amylin/calcitonin agonists

When mechanisms of action collide in unexpected ways

GLP-1

+2

Obesity Week 2025 Medications

Nov 14, 2025

•

31 min read

Obesity Week 2025 Medications

Orforglipron, HRS 9531, MET-097, Eloralintide and Mazdutide, OH MY!

GLP-1

+1

ADA Conference 2025: CagriSema

Jun 24, 2025

•

9 min read

ADA Conference 2025: CagriSema

Novo's Dual Amylin-GLP1 agonist shows promise but caveats apply

The Incretin Space

The Incretin Space

A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretin in medicine


Home

© 2026 The Incretin Space.
beehiivPowered by beehiiv